e.-coli-nissle
ApprovedSmall molecule
e.-coli-nissle is one of 73 small molecule programs targeting Diabetes Mellitus. It is currently in Approved.
2
Indications
2
Total Trials
0
Active Trials
72
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
286 competitors in Diabetes Mellitus
#DrugCompanyPhaseTrials
1Novonorm
GGemini Therapeutics, Inc.
Phase 3
e.-coli-nissle
UUniversity of Oulu
Approved
Rosiglitazone/metformin
GSKPhase 3
Short-Acting Insulin
MMukoviszidose Institut gGmbH
Phase 3
Trulicity
Eli LillyPreclinical
Byetta
AstraZenecaPreclinical
Simponi
Johnson & JohnsonPreclinical
Paxil CR
GSKPreclinical
Edarbi
TakedaPreclinical
NOVOLIN R
Novo NordiskPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for e.-coli-nissle. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity of Oulu